Alveron Pharma is a technology company.
Alveron Pharma has raised $5.0M across 1 funding round.
Alveron Pharma has raised $5.0M in total across 1 funding round.
Alveron Pharma has raised $5.0M in total across 1 funding round.
Alveron Pharma's investors include Broadview Ventures.
Alveron Pharma is a clinical-stage biopharmaceutical company developing OKL-1111, a cyclodextrin-based injectable drug that reverses the effects of anticoagulants and platelet inhibitors to treat intracranial hemorrhage (ICH), such as hemorrhagic stroke.[1][2][3][4][5][6] It serves patients on blood thinners experiencing life-threatening brain bleeds, addressing the critical problem of delayed reversal due to agent-specific therapies that require identification and complex preparation, which worsen outcomes like hematoma expansion, mortality, and morbidity.[1][2][5] The company, based in Nijmegen (with some references to Rotterdam), Netherlands, was recently bolstered by a €5M Series Seed extension funding round led by Broadview Ventures, signaling strong growth momentum as OKL-1111 advances post-Phase 1 clinical trials toward broader validation.[1][2][6]
Alveron Pharma was incorporated in March 2019 as a joint venture between Okklo Life Sciences (focused on therapeutic cyclodextrins) and Sanquin, the Dutch Blood Foundation, acquiring rights to OKL-1111 from their collaborative research project.[1][3] The drug's foundation stems from patented work by Joost Meijers (University of Amsterdam/Sanquin), inventor of "Cyclodextrins as procoagulants," which underpins the company's universal reversal approach.[3] Early traction included the €5M seed extension in 2025 led by Broadview Ventures, with participation from Sanquin, Thuja Capital, Waterman Ventures, and Oost NL, enabling Phase 1 completion and pivotal advancement.[1][6] Leadership features CEO Ben Nichols, alongside experts like Alex Hash (CMC specialist from Mundipharma), Alex Zwiers (regulatory consultant for coagulation products), and Edwin (PharmD with clinical pharmacology experience), humanizing its push from research origins to clinical promise.[3]
Alveron rides the surging demand for rapid-response therapies in an aging population increasingly on anticoagulants and antiplatelets, where ICH affects millions annually with high mortality due to unmet reversal needs.[1][2] Timing is ideal amid rising stroke incidence and investor focus on cardiovascular innovations, as seen in Broadview Ventures' mission-driven support for stroke therapeutics.[1][2] Market forces like expanding anticoagulant use (e.g., DOACs) and gaps in antiplatelet reversal favor its broad-spectrum approach, potentially slashing treatment delays and influencing emergency protocols globally.[2][5] By pioneering cyclodextrin-based procoagulants, Alveron shapes the hemostasis ecosystem, enabling faster interventions that could redefine outcomes in neurocritical care.[3][6]
Alveron Pharma stands poised for Phase 2 trials and partnerships, leveraging its €5M funding to accelerate OKL-1111 toward approval amid high unmet need in ICH reversal.[1][5][6] Trends like AI-driven diagnostics and personalized anticoagulation will amplify its universal agent's value, potentially expanding to trauma and surgical bleeding markets.[3][4] Its influence may evolve from niche innovator to ecosystem leader, delivering the first single-dose brain bleed solution and transforming hemorrhagic stroke survival—echoing its origins in bold cyclodextrin research to save lives where time is brain.[2][6]
Alveron Pharma has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $5.0M Seed | Broadview Ventures |